Effect of Metaxalone 640 mg (M640) on Driving, Cognition, and EEG Dynamics Compared to Tizanidine 8 mg in Adults

ClinicalTrials.gov ID: NCT07932613

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07932613. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Assessment of the Effect of Metaxalone Tablets, 640 mg (M640) on Driving Ability, Cognition, and Electroencephalographic (EEG) Dynamics Compared to Tizanidine 8 mg in Adult Participants: A Prospective, Single-blind, Within-subject Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Participant takes a single pill after eating, takes a driving test on a simulator, takes thought and concentration computerized tests

Study identification

NCT ID: NCT07932613
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: Primus Pharmaceuticals; Industry
Enrollment: 20 participants

Conditions and interventions

Conditions

Healthy Participant

Interventions

Metaxalone Pill Drug
tizanidine 8 mg Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 15, 2026 (Estimated)
Primary completion: Jul 15, 2027 (Estimated)
Completion: Oct 15, 2027 (Estimated)
Last update posted: Nov 12, 2026

2026 – 2027

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Perseverance Research Center, LLC	Scottsdale	Arizona	85253	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07932613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2026 · Synced Nov 14, 2026